Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pimavanserin vs Quetiapine for Parkinson's Disease Psychosis
NCT04164758Phase 2Terminated
- Sponsor
- Acadia Pharmaceuticals
- Start
- Oct 2019
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pimavanserin in Parkinson's disease (PD), sponsored by Acadia Pharmaceuticals. Started Oct 2019; status: terminated.
02
Drugs
pimavanserin
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04164758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04164758.